Publications by authors named "Cynthia D Evans"

Claim this Profile
D
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.
Jennifer A Zimmer, John R Sims, Cynthia D Evans, Emel Serap Monkul Nery, Hong Wang

J Prev Alzheimers Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease.
Garrett R Mullins, Paul Ardayfio, Ivelina Gueorguieva, Greg Anglin, Jason Bailey, Cynthia D Evans

Alzheimers Dement (N Y)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab exposure-response in early symptomatic Alzheimer's disease.
Ivelina Gueorguieva, Kay Chow, Laiyi Chua, Sergey Shcherbinin, Jennifer A Zimmer, Cynthia D Evans

Alzheimers Dement· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.
Jennifer A Zimmer, Paul Ardayfio, Hong Wang, Rashna Khanna, Cynthia D Evans

JAMA Neurol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials.
Cynthia D Evans, JonDavid Sparks, Scott W Andersen, Dawn A Brooks, Paula M Hauck

Alzheimers Dement· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
Cynthia D Evans, John R Sims

JAMA· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
John R Sims, Jennifer A Zimmer, Cynthia D Evans, Ming Lu, Paul Ardayfio

JAMA· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease.
Sergey Shcherbinin, Amanda Morris, Ixavier A Higgins, Ilke Tunali, Ming Lu, Cynthia D Evans

Alzheimers Dement (N Y)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Sergey Shcherbinin, Cynthia D Evans, Ming Lu, Scott W Andersen, Michael J Pontecorvo

JAMA Neurol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer's Disease Dementia.
Albert C Lo, Cynthia Duggan Evans, Michele Mancini, Hong Wang, Sergey Shcherbinin

J Alzheimers Dis Rep· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis